Hospital days in risperidone-treated patients

被引:7
|
作者
Dickson, RA
Dalby, JT
Addington, D
Williams, R
McDougall, GM
机构
[1] Calgary Gen Hosp, Peter Lougheed Ctr, Reg Clin Dept Psychiat, Carnat Ctr,Specialized Programs Div, Calgary, AB T1Y 6J4, Canada
[2] Univ Calgary, Fac Med, Dept Psychiat, Calgary, AB T2N 1N4, Canada
[3] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[4] Univ Victoria, Victoria, BC V8W 2Y2, Canada
[5] Royal Jubilee Hosp, Schizophrenia Program, Victoria, BC, Canada
关键词
schizophrenia; risperidone; outcomes; hospital days;
D O I
10.1177/070674379904400907
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To compare inpatient hospital days of a group of "real world" schizophrenia-spectrum patients for 3 years prior to and 3 years after risperidone initiation. Method: This is a retrospective cohort study using a mirror-image design of hospital days in 120 patients over a 6-year period. Hospital admission and discharge information was obtained from chart review and database extraction at 3 outpatient treatment sites. The sample comprised all patients attending these clinics who were prescribed risperidone during the first year of the drug's release. Results: Patients separated into 3 treatment groups. those who were prescribed risperidone for 3 uninterrupted years (N = 35), those who interrupted but resumed risperidone use and were prescribed the drug at 3 years (N = 8), and those who discontinued risperidone during the 3-year follow-up period (N = 77). The group continuing risperidone to 3 years demonstrated a significant decrease in hospital days after risperidone treatment, in contrast to the other 2 groups. The reduction in inpatient days for the total sample was not statistically significant. Conclusion: In this outpatient clinic sample, the 29% of patients who continued on risperidone showed a significant reduction in inpatient hospital days, from an average of 17.2 days per year in the 3 years before risperidone treatment to an average of 2.1 days per year for the 3 years of risperidone treatment.
引用
收藏
页码:909 / 913
页数:5
相关论文
共 50 条
  • [11] Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys
    Calarge, Chadi A.
    Mills, James A.
    Karaviti, Lefkothea
    Teixeira, Antonio L.
    Zemel, Babette S.
    Garcia, Jose M.
    JOURNAL OF PEDIATRICS, 2018, 201 : 245 - 251
  • [12] Triglyceride, cholesterol and weight changes among risperidone-treated youths - A retrospective study
    Martin, A
    L'Ecuyer, S
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2002, 11 (03) : 129 - 133
  • [13] Triglyceride, cholesterol and weight changes among risperidone-treated youthsA retrospective study
    A. Martin
    S. L'Ecuyer
    European Child & Adolescent Psychiatry, 2002, 11 : 129 - 133
  • [14] LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia
    Tislerova, Barbora
    Brunovsky, Martin
    Horacek, Jiri
    Novak, Tomas
    Kopecek, Miloslav
    Mohr, Pavel
    Krajca, Vladimir
    NEUROPSYCHOBIOLOGY, 2008, 58 (01) : 1 - 10
  • [15] Hospital days in clozapine-treated patients
    Dickson, RA
    Dalby, JT
    Williams, R
    Warden, SJ
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1998, 43 (09): : 945 - 948
  • [16] Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth
    Calarge, Chadi A.
    Murry, Daryl J.
    Ziegler, Ekhard E.
    Arnold, L. Eugene
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2016, 26 (05) : 471 - 477
  • [17] Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in risperidone-treated schizophrenic patients
    Dresel, S
    Tatsch, K
    Dähne, I
    Mager, T
    Scherer, J
    Hahn, K
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (07) : 1138 - 1142
  • [18] Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data
    Martin, A
    Scahill, L
    Anderson, GM
    Aman, M
    Arnold, LE
    McCracken, J
    McDougle, CJ
    Tierney, E
    Chuang, S
    Vitiello, B
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (06): : 1125 - 1127
  • [19] Risperidone-treated children and adolescents with behavioral disorders: Do drug dose and patients' gender and age relate to drug and metabolite plasma levels?
    Piacentino, D.
    Groezinger, M.
    Saria, A.
    Scolati, F.
    Arcangeli, D.
    Girardi, P.
    Pompili, M.
    Conca, A.
    EUROPEAN PSYCHIATRY, 2017, 41 : S104 - S104
  • [20] UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder
    Yaowaluck Hongkaew
    Sadeep Medhasi
    Ekawat Pasomsub
    Nattawat Ngamsamut
    Apichaya Puangpetch
    Natchaya Vanwong
    Monpat Chamnanphon
    Penkhae Limsila
    Chuthamanee Suthisisang
    Bob Wilffert
    Chonlaphat Sukasem
    The Pharmacogenomics Journal, 2018, 18 : 740 - 748